Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2020-06-03 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2020-06-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common stock, including details about the shares offered, the price, and the closing date. It also references exhibits such as the underwriting agreement and legal opinions. There are no financial statements or detailed financial performance data included, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a financing event (public offering of shares). Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not just a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2020-06-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes offering details such as number of shares, pricing, underwriting information, risk factors, use of proceeds, and other disclosures typical of a securities offering document. The presence of terms like 'Prospectus Supplement', 'Common Stock', 'Offering Price', 'Underwriting', and references to SEC rules and registration numbers clearly indicate this is a capital raising document. It is not an annual report, earnings release, management discussion, or any other type of report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, supporting a high confidence in classification.
2020-05-29 English
S-3MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Mersana Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The document includes details about the offering, registration fee, and exhibits such as legal opinions and consents. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 8067 characters, which is substantive and contains the full registration statement text, not just an announcement.
2020-05-29 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of common stock. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document is a registration and offering prospectus supplement, which is a capital markets document related to fundraising and securities issuance. It is not a financial report, earnings release, management discussion, or any other type of corporate filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement but the actual offering document.
2020-05-28 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it reports an event on May 27, 2020, specifically the issuance of a press release about interim data from a Phase 1 study expansion. The document includes the press release as an exhibit but does not contain detailed financial statements or comprehensive financial data. The length is 3270 characters, which is relatively short and consistent with a current report rather than a full financial report. There is no indication of an earnings release, annual report, or other detailed financial disclosures. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-05-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.